BGE-102 was developed from a hit compound identified via HitGen's industry-leading DEL (DNA-Encoded Library) technology platform ... "We are very pleased to see BGE‑102 reach the Phase 2 milestone," said Dr.
Randomized, double-blind, placebo-controlled, dose-ranging trial evaluating three once-daily oral doses of BGE-102 in participants with elevated systemic inflammation and additional cardiovascular risk factors ... .